+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Viral Transfection Reagents and Systems Market, 2020-2030

  • ID: 5116507
  • Report
  • March 2020
  • Region: Global
  • 228 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 10x Genomics
  • Caribou Biosciences
  • Fuda Cancer Hospital
  • Inserm
  • Novartis
  • Sanofi

Overview

Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain. Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma® (USD 2.1 million) and Luxtruna® (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.
Scope of the Reports

The ‘Non-Viral Transfection Reagents and Systems Market, 2020-2030’ report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features:


  • A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.
  • An insightful 2X2 representation, highlighting the competitiveness analysis of non-viral transfection system developers captured in our database, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).
  • An analysis highlighting potential strategic partners segregated based on likelihood of entering into collaboration with non-viral transfection system developers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, type of vector and company size.
  • An analysis of the big pharma players engaged in this domain, featuring a heat map based on parameters, such as type of initiative, type of therapy and target therapeutic area.
  • An analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.
  • An in-depth analysis of close to 14,000 patents related to non-viral transfection systems that have been filed/granted since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority/patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted/filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, cost per transfection, share of non-viral systems within the transfections market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the future opportunity across [A] non-viral transfection systems (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):


  • George Eastwood (Vice-President of Business Development, Kytopen)
  • Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 10x Genomics
  • Caribou Biosciences
  • Fuda Cancer Hospital
  • Inserm
  • Novartis
  • Sanofi

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Transfection
3.3. Applications of Transfection
3.3.1. Advanced Therapy Medicinal Product Development
3.3.2. Gene Silencing
3.3.3. Generation of Stable Cell Lines
3.3.4. Large-scale Protein Production
3.3.5. Stem Cell Engineering
3.4. Methods of Transfection
3.4.1. Viral Transfection
3.4.1.1. Types of Viral Vectors
3.4.1.1.1. Adeno-associated Vector
3.4.1.1.2. Adenoviral Vector
3.4.1.1.3. Herpes Virus
3.4.1.1.4. Lentiviral
3.4.1.1.5. Retroviral
3.4.2. Non-Viral Transfection
3.4.2.1. Chemical Methods
3.4.2.1.1. Lipoplexes
3.4.2.1.2. Polyplexes
3.4.2.1.3. Lipo-polyplexes
3.4.2.1.4. Dendrimers
3.4.2.1.5. Cell Penetrating Peptides
3.4.2.2. Physical Methods
3.4.2.2.1. Electroporation
3.4.2.2.2. Gene Gun
3.4.2.2.3. Sonoporation
3.4.2.2.4. Microinjection
3.4.2.2.5. Magnetofection
3.5. Future Perspectives
4. MARKET LANDSCAPE: NON-VIRAL TRANSFECTION SYSTEMS
4.1. Chapter Overview
4.2. Non-Viral Transfection Reagents: Market Landscape
4.2.1.1. Analysis by Type of Carrier Used
4.2.1.2. Analysis by Type of Molecule Delivered
4.2.1.3. Analysis of Developers by Year of Establishment
4.2.1.4. Analysis of Developers by Company Size
4.2.1.5. Analysis of Developers by Geography
4.3. Electroporation-based Transfection Systems: Market Landscape
4.3.1.1. Analysis by Type of Molecule Delivered
4.3.1.2. Analysis by Compatible Cell Type
4.3.1.3. Analysis of Developers by Year of Establishment
4.3.1.4. Analysis of Developers by Company Size
4.3.1.5. Analysis of Developers by Geography
4.4. Other Non-Viral Transfection Systems: Market Landscape
4.4.1.1. Analysis by Type of Molecule Delivered
4.4.1.2. Analysis by Compatible Cell Type
4.4.1.3. Analysis of Developers by Year of Establishment
4.4.1.4. Analysis of Developers by Company Size
4.4.1.5. Analysis of Developers by Geography
5. NON-VIRAL TRANSFECTION SYSTEMS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology and Key Parameters
5.3. Competitiveness Analysis: Transfection Reagent Providers
5.3.1. Competitiveness Analysis: Transfection Reagent Providers based in North America
5.3.2. Competitiveness Analysis: Transfection Reagent Providers based in Europe
5.3.3. Competitiveness Analysis: Transfection Reagent Providers based in Asia-Pacific
5.4. Competitiveness Analysis: Electroporation-based Transfection System
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Transfection Reagent Providers
6.2.1. Altogen Biosystems
6.2.1.1. Company Overview
6.2.1.2. Recent Developments and Future Outlook
6.2.2. MilliporeSigma
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Recent Developments and Future Outlook
6.2.3. OZ Biosciences
6.2.3.1. Company Overview
6.2.3.2. Recent Developments and Future Outlook
6.2.4. Thermo Fisher Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Recent Development and Future Outlook
6.3. Gene Gun-based Transfection System Providers
6.3.1. Bio-Rad Laboratories
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Ningbo Scientz Biotechnology
6.3.2.1. Company Overview
6.4. Electroporation-based Transfection System Providers
6.4.1. BEX
6.4.1.1. Company Overview
6.4.2. BTX (Harvard Bioscience Division)
6.4.2.1. Company Overview
6.4.2.2. Recent Developments and Future Outlook
6.4.3. MaxCyte
6.4.3.1. Company Overview
6.4.3.2. Financial Information
6.4.3.3. Recent Developments and Future Outlook
6.4.4. NepaGene
6.4.4.1. Company Overview
6.5. Other Non-Viral Transfection System Providers
6.5.1. Celsion Corporation
6.5.1.1. Company Overview
6.5.1.2. Recent Developments and Future Outlook
6.5.2. Genprex
6.5.2.1. Company Overview
6.5.2.2. Financial Information
6.5.2.3. Recent Developments and Future Outlook
6.5.3. Inovio Pharmaceuticals
6.5.3.1. Company Overview
6.5.3.2. Financial Information
6.5.3.3. Recent Developments and Future Outlook
7. POTENTIAL STRATEGIC PARTNERS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Potential Strategic Partners for Non-Viral Transfection System Providers
7.3.1.1. Key Industry Partners
7.3.2. Key Non-Industry / Academic Partners
7.4. Potential Strategic Partners for Non-Viral Transfection System Providers
7.4.1.1. Key Industry Partners
7.4.2. Key Non-Industry / Academic Partners
7.5. Potential Strategic Partners for Non-Viral Transfection System Providers
7.5.1.1. Key Industry Partners
7.5.2. Key Non-Industry / Academic Partners
8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. Scope and Methodology
8.2.1. Analysis by Type of Initiative
8.2.2. Analysis by Type of Therapy
8.2.3. Analysis by Therapeutic Area
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Non-Viral Transfection Systems: Clinical Trials Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Analysis by Type of Sponsor
9.3.5. Analysis by Type of Therapy
9.3.6. Analysis by Target Therapeutic Area
9.3.7. Analysis by Trial Design
9.3.8. Analysis by Type of Patient Allocation Model Used
9.3.9. Analysis by Type of Masking Adopted
9.3.10. Analysis by Type of Intervention
9.3.11. Analysis by Trial Purpose
9.3.12. Analysis by Number of Trials and Geographical Location
9.3.13. Analysis by Enrolled Patient Population and Geographical Location
9.3.14. Analysis by Number of Trials, Trial Status and Geographical Location
9.3.15. Analysis by Enrolled Patient Population, Trial Status and Geographical
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Key Parameters and Methodology
10.3. Non-Viral Transfection Systems: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geographical Location
10.3.3. Analysis by Type of Applicant
10.3.4. Analysis by CPC Symbol
10.3.5. Word Cloud: Emerging Focus Areas
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Non-Viral Transfection Systems: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Geography
10.5. Non-Viral Transfection Systems: Patent Valuation Analysis
11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Analysis by Year of Publication
11.4. Analysis by Publication Focus
11.5. Analysis by Type of Molecule Delivered
11.6. Analysis by Target Therapeutic Area
11.7. Word Cloud: Important Cells and Cell Lines
11.8. Leading Players: Geographical Analysis by Number of Publications
11.9. Key Journals: Analysis by Number of Publications
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Non-Viral Transfection Systems Market, 2020-2030
12.4. Non-Viral Transfection Systems Market: Distribution by Transfection Method, 2020 and 2030
12.5. Non-Viral Transfection Systems Market: Distribution by End-User, 2020 and 2030
12.6. Non-Viral Transfection Systems Market: Distribution by Area of
12.7. Non-Viral Transfection Systems Market: Distribution by Regions, 2020 and 2030
12.7.1. Non-Viral Transfection Systems Market in North America, 2020-2030
12.7.1.1. Non-Viral Transfection Systems Market in North America, Distribution by End-User
12.7.1.1.1. Non-Viral Transfection Systems Market in North America: Share of Pharmaceutical Companies, 2020-2030
12.7.1.1.2. Non-Viral Transfection Systems Market in North America: Share of
12.7.1.1.3. Non-Viral Transfection Systems Market in North America: Share of Other End-Users, 2020-2030
12.7.1.2. Non-Viral Transfection Systems Market in North America, Distribution by Area of Application
12.7.1.2.1. Non-Viral Transfection Systems Market in North America for Research Application, 2020-2030
12.7.1.2.2. Non-Viral Transfection Systems Market in North America for Clinical Application, 2020-2030
12.7.2. Non-Viral Transfection Systems Market in Europe, 2020-2030
12.7.2.1. Non-Viral Transfection Systems Market in Europe, Distribution by End-User
12.7.2.1.1. Non-Viral Transfection Systems Market in Europe: Share of Pharmaceutical Companies, 2020-2030
12.7.2.1.2. Non-Viral Transfection Systems Market in Europe: Share of Academic and Research Institutions, 2020-2030
12.7.2.1.3. Non-Viral Transfection Systems Market in Europe: Share of Other End-Users, 2020-2030
12.7.2.2. Non-Viral Transfection Systems Market in Europe, Distribution by Area of Application
12.7.2.2.1. Non-Viral Transfection Systems Market in Europe for Research Application, 2020-2030
12.7.2.2.2. Non-Viral Transfection Systems Market in Europe for Clinical Application, 2020-2030
12.7.3. Non-Viral Transfection Systems Market in Asia-Pacific, 2020-2030
12.7.3.1. Non-Viral Transfection Systems Market in Asia-Pacific, Distribution by End-User
12.7.3.1.1. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Pharmaceutical Companies, 2020-2030
12.7.3.1.2. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Academic and Research Institutions, 2020-2030
12.7.3.1.3. Non-Viral Transfection Systems Market in Asia-Pacific: Share of Other End-Users, 2020-2030
12.7.3.2. Non-Viral Transfection Systems Market in Asia-Pacific, Distribution by Area of Application
12.7.3.2.1. Non-Viral Transfection Systems Market in Asia-Pacific for Research Application, 2020-2030
12.7.3.2.2. Non-Viral Transfection Systems Market in Asia-Pacific for Clinical Application, 2020-2030
12.7.4. Non-Viral Transfection Systems Market in Rest of the World, 2020-2030
12.7.4.1. Non-Viral Transfection Systems Market in Rest of the World, Distribution by End-User
12.7.4.1.1. Non-Viral Transfection Systems Market in Rest of the World: Share of Pharmaceutical Companies, 2020-2030
12.7.4.1.2. Non-Viral Transfection Systems Market in Rest of the World: Share of Academic and Research Institutions, 2020-2030
12.7.4.1.3. Non-Viral Transfection Systems Market in Rest of the World: Share of Other End-Users, 2020-2030
12.7.4.2. Non-Viral Transfection Systems Market in Rest of the World, Distribution by Area of Application
12.7.4.2.1. Non-Viral Transfection Systems Market in Rest of the World for Research Application, 2020-2030
12.7.4.2.2. Non-Viral Transfection Systems Market in Rest of the World for Clinical Application, 2020-2030
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Kytopen
13.2.1. Interview Transcript: George Eastwood, Vice-President Business Development
13.3. Polyplus-transfection
13.3.1. Interview Transcript: Claudia Andretta, Global Business Development Manager, Clinical
14. CONCLUSION15. APPENDIX 1: TABULATED DATA
Note: Product cover images may vary from those shown
  • 10x Genomics
  • 20Med Therapeutics
  • AAT Bioquest
  • Abbiotec
  • Applied Biological Materials
  • Acuitas Therapeutics
  • Agilent Technologies
  • Allergan
  • Altogen Biosystems
  • AstraZeneca
  • Avanti Polar Lipids
  • Avectus Healthcare Solutions
  • BEX
  • Bio Basic
  • Biotechnologies
  • Biomaterials USA
  • BioNTech Protein
  • Biontex Laboratories
  • Biopact
  • Bio-Rad Laboratories
  • BIOTOOLS
  • BioWare Technologies
  • Bristol-Myers Squibb
  • Broad Institute
  • BTX
  • Canvax
  • Caribou Biosciences
  • Casebia Therapeutics
  • Celetrix
  • Cell and Gene Therapy Catapult
  • Cell Applications
  • Cellectis
  • Celsion Corporation
  • Chinese University of Hong Kong
  • Cosmo Bio
  • Creative Biolabs
  • CRISPR Therapeutics
  • Cybrexa Therapeutics
  • Danisco
  • Drummond Scientific
  • Editas Medicine
  • Eli Lilly
  • Emisphere Technologies
  • enGene
  • Enzo Life Sciences
  • Eppendorf
  • Exicure
  • Exon Biosciences
  • ExpreS2ion Biotechnologies
  • Eyevensys
  • EZ Biosystems
  • Feldan Therapeutics
  • FormuMax Scientific
  • Fuda Cancer Hospital
  • Fugent
  • FUJIFILM Irvine Scientific
  • G-Biosciences
  • Gemini Bio-Products
  • GeneCopoeia
  • GeneDireX
  • GeneOne Life Science
  • Genlantis
  • Genprex
  • GenScript
  • Gilead Sciences
  • GlaxoSmithKline
  • Gradalis
  • Harvard College
  • Helixmith
  • Horizon Discovery
  • Ichor Medical Systems
  • Icosagen
  • IGEA
  • Immudicon
  • In-Cell-Art
  • indee labs
  • Infinitesimal
  • Inovio Pharmaceuticals
  • Inserm
  • iNtRON Biotechnology
  • InvivoGen
  • Ionis Pharmaceuticals
  • Janssen Pharmaceutica
  • KSQ Therapeutics
  • Kytopen
  • Lemonex
  • Locate Bio
  • Lonza
  • Massachusetts Institute of Technology
  • MaxCyte
  • Merck
  • MilliporeSigma
  • Miltenyi Biotec
  • Mirai Medical
  • Mirus Bio
  • Moderna
  • N4 Pharma
  • nanoTherics
  • Narishige
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • NepaGene
  • Neuromics
  • NGM Biopharmaceuticals
  • Ningbo Scientz Biotechnology
  • Novartis
  • Novo Nordisk
  • Novozymes
  • NTrans Technologies
  • OpenCell Technologies
  • OrganoLinX
  • OriGene Technologies
  • OZ Biosciences
  • Pfizer
  • pHion Therapeutics
  • Plexxikon
  • Polyplus-transfection
  • Polysciences
  • Poseida Therapeutics
  • Precigen
  • Precision Bio Laboratories
  • Precision BioSciences
  • Precision NanoSystems
  • Promega Corporation
  • PromoCell
  • Proteacel
  • Qiagen
  • Regeneron Pharmaceuticals
  • RJH Biosciences
  • Roche
  • Sanofi
  • Santa Cruz Biotechnology
  • Scinogy
  • ScreenFect
  • SignaGen Laboratories
  • Sino Biological
  • SQZ Biotech
  • Stanford University
  • Stoelting
  • Sutter Instrument
  • Synvolux Products
  • System Biosciences
  • Taipei Veterans General Hospital
  • Takara Bio
  • Tecrea
  • Thermo Fisher Scientific
  • Torque Pharmaceuticals
  • Touchlight Genetics
  • T-Pro Biotechnology
  • transOMIC technologies
  • Tritech Research
  • University of Pittsburgh
  • University of Texas
  • Vor Biopharma
  • Wealtec Bioscience
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...